Price Comparison
IGF-DES
Growth Factor Analog Peptide
2 of 2 vendors
| Vendor | Price | 10mg cost | Updated | Actions |
|---|---|---|---|---|
| Qureshi Labs 7/10 COA ✓Ships: USCredit/debit card Verification & shipping7/10 COA ✓Ships: USCredit/debit card | $58.49 | $175.47Checked jul 25, 2026 | Jul 25, 2026 | Buy IGF-DES from Qureshi Labs |
| Alpha Peptides 8/10 COA ✓Ships: USCredit/debit card Verification & shipping8/10 COA ✓Ships: USCredit/debit card | $23.26 | $232.60Checked jul 31, 2026 | Jul 31, 2026 | Buy IGF-DES from Alpha Peptides |
Research details
IGF-DES — research data
Half-life~20–30 minutes (very short, no IGFBP binding). Must be used immediately post-workout for anabolic window.
Regulatory statusNot FDA-approved
NCAA D1Banned
Overview
About IGF-DES
Mechanism of action
Truncated IGF-1 lacking the first 3 amino acids; does NOT bind IGF binding proteins (IGFBPs) — results in 10x greater potency at the receptor vs. standard IGF-1 LR3; direct, unhindered IGF-1 receptor activation at injection site.
Safety profile
Hypoglycemia risk, localized muscle swelling, potential for disproportionate site growth, insulin resistance, water retention. Similar risk profile to IGF-1 LR3. · More potent than IGF-1; hypoglycemia proven; tumor promotion concern; mechanistic risk basis
Storage
Stability & handling
Lyophilized (powder)−20°Clong-term stable
Reconstituted2–8°Cwithin 14–30 days
Related pages
More on IGF-DES
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- Des(1-3)IGF-I lacks the N-terminal Gly-Pro-Glu tripeptide and has been isolated from bovine colostrum, human brain tissue, and porcine uterus as a natural post-translational processing product; it demonstrates approximately 10-fold greater cellular potency than full-length IGF-I primarily because it binds negligibly to IGF-binding proteins (IGFBPs), leaving more free peptide available at the receptor.
- A 1989 Biochemical Journal study established the core mechanism: IGFBP preparations that potently inhibited IGF-1 and IGF-2 bioactivity had no inhibitory effect on des-(1-3)-IGF-I, directly demonstrating that biological potency inversely correlates with IGFBP binding affinity.